Takeda (TAK) has announced that the Japanese Ministry of Health, Labour and Welfare has granted approval for the use of the HYQVIA 10% Subcutaneous injection set in patients with agammaglobulinemia or hypogammaglobulinemia. HYQVIA stands as the inaugural plasma-derived therapy for subcutaneous administration in Japan, comprising a combination of an Immunoglobulin 10% vial and a Recombinant Human Hyaluronidase PH20 vial.
"We are thrilled that HYQVIA, already approved in over 40 countries globally, has now received approval in Japan," stated Naoyoshi Hirota, Regional Head of Research & Development for Takeda's Plasma-Derived Therapies Business Unit in Japan.
The material has been provided by InstaForex Company - www.instaforex.com
"We are thrilled that HYQVIA, already approved in over 40 countries globally, has now received approval in Japan," stated Naoyoshi Hirota, Regional Head of Research & Development for Takeda's Plasma-Derived Therapies Business Unit in Japan.
The material has been provided by InstaForex Company - www.instaforex.com